Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Pharvaris N.V.NASDAQ: PHVS

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of €6.81M rose 39.2% year over year, ahead of the -7.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +39.2% holds above the trailing-twelve-month pace of -7.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
€6.81M+2.6% QoQ
Last fiscal yearDec 2025
€19.05M+17.5% YoY
LTMSep 2026
€17.97M-7.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.2%——
1 year+17.5%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
19.05M EUR
Year-over-year change
+17.5%
4-year CAGR
+23.5%

Stock-Based Compensation vs competitors

How PHVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.1% is the 5th highest of 7, against a peer median of +60.5%.
  • Over three fiscal years its annual growth of +18.8% compares with a peer median of +5.6%.
PHVS Competitors
Stock-Based Compensation for PHVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$172.73B USD+92559.3%-2.6%16.8%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$121.89M USD+50.0%+23.9%13.0%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$72.84M USD+70.9%+5.6%11.2%
VERAVera Therapeutics, Inc.LTM Jun 2026$49.78M USD+71.5%+62.2%—
PHVSPharvaris N.V.LTM Sep 2026€17.97M EUR-7.1%+18.8%—
RLYBRallybio CorporationLTM Mar 2026$4.05M USD-48.0%-17.6%471.8%
PHARPharming Group N.V.LTM Mar 2026$3.48M USD-33.4%—0.9%
Peer median (excluding PHVS) —+60.5%+5.6%13.0%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.66M)(75.65M)(99.83M)(132.4M)(173.71M)
Depreciation & Amortization77.37K152.94K257.55K269.56K418.35K
Deferred Income Tax00000
Stock-Based Compensation8.2M11.35M10.66M16.21M19.05M
Change in Working Capital1.58M8.38M(5.86M)5.89M7.62M
Accounts Receivables(130.5K)317.61K(41.05K)(34.32K)(331.34K)
Inventory00000
Accounts Payables00000
Other Working Capital1.71M8.06M(5.82M)5.92M7.96M
Other Non-Cash Items(11.79M)(11.39M)1.72M(10.1M)9.54M
Operating Cash Flow(44.6M)(67.16M)(93.05M)(120.13M)(137.07M)
Capital Expenditures(130.03K)(124.3K)(89.98K)(538.09K)(164.62K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(130.03K)(124.3K)(89.98K)(538.09K)(164.62K)
Debt Repayment0(119.53K)(220.51K)(159.66K)(219.01K)
Common Stock Issued156.83M9.61M342.91M2.24M171.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(13.15M)(839.97K)(17.3M)592K(10.91M)
Financing Cash Flow143.67M8.65M325.39M2.68M160.61M
Effect of Forex Changes11.78M11.12M(2.86M)7.49M(12.42M)
Net Change in Cash110.72M(47.52M)229.39M(110.5M)10.95M
Free Cash Flow(44.73M)(67.29M)(93.14M)(120.67M)(137.24M)

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.